Pulmonary Arterial Hypertension market

View All

WINREVAIR Approval for Pulmonary Arterial Hypertension Treatment: Is It A Game-Changer for Merck?

Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension. An estimated prevalence of pulmonary hypertension at the pop...

Find More

pulmonary arterial hypertension
New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Domain

Pulmonary arterial hypertension is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. Pulmonary arterial hypertension is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization. The term Pulmonary arterial hypert...

Find More

Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Therapies

Pulmonary Arterial Hypertension (PAH) is a chronic, life-alarming disease that advances over time. It is a rare disease characterized by the increased blood pressure in the arteries of the lungs. It is somehow different from normal high pressure in a way that blood pressure rises only in the arteries that carry blo...

Find More